Literature DB >> 23125072

Medications development for opioid abuse.

S Stevens Negus1, Matthew L Banks.   

Abstract

Here we describe methods for preclinical evaluation of candidate medications to treat opioid abuse and dependence. Our perspective is founded on the propositions that (1) drug self-administration procedures provide the most direct method for assessment of medication effects, (2) procedures that assess choice between opioid and nondrug reinforcers are especially useful, and (3) the states of opioid dependence and withdrawal profoundly influence both opioid reinforcement and the effects of candidate medications. Effects of opioid medications on opioid choice in nondependent and opioid-dependent subjects are reviewed. Various nonopioid medications have also been examined, but none yet have been identified that safely and reliably reduce opioid choice. Future research will focus on (1) strategies for increasing safety and/or effectiveness of opioid medications, and (2) continued development of nonopioids such as inhibitors of endocannabinoid catabolic enzymes or inhibitors of opioid-induced glial activation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23125072      PMCID: PMC3530034          DOI: 10.1101/cshperspect.a012104

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Med        ISSN: 2157-1422            Impact factor:   6.915


  47 in total

1.  Method for training operant responding and evaluating cocaine self-administration behavior in mutant mice.

Authors:  S B Caine; S S Negus; N K Mello
Journal:  Psychopharmacology (Berl)       Date:  1999-11       Impact factor: 4.530

2.  Attenuation of spontaneous opiate withdrawal in mice by the anandamide transport inhibitor AM404.

Authors:  Ignacio Del Arco; Miguel Navarro; Ainhoa Bilbao; Belén Ferrer; Daniele Piomelli; Fernando Rodríguez De Fonseca
Journal:  Eur J Pharmacol       Date:  2002-11-01       Impact factor: 4.432

Review 3.  Principles of drug abuse liability assessment in laboratory animals.

Authors:  Nancy A Ator; Roland R Griffiths
Journal:  Drug Alcohol Depend       Date:  2003-06-05       Impact factor: 4.492

4.  Attenuation of morphine tolerance, withdrawal-induced hyperalgesia, and associated spinal inflammatory immune responses by propentofylline in rats.

Authors:  Vasudeva Raghavendra; Flobert Y Tanga; Joyce A DeLeo
Journal:  Neuropsychopharmacology       Date:  2004-02       Impact factor: 7.853

5.  Endogenous cannabinoid, 2-arachidonoylglycerol, attenuates naloxone-precipitated withdrawal signs in morphine-dependent mice.

Authors:  T Yamaguchi; Y Hagiwara; H Tanaka; T Sugiura; K Waku; Y Shoyama; S Watanabe; T Yamamoto
Journal:  Brain Res       Date:  2001-08-03       Impact factor: 3.252

6.  Effects of buprenorphine sublingual tablet maintenance on opioid drug-seeking behavior by humans.

Authors:  Mark K Greenwald; Kory J Schuh; John A Hopper; Charles R Schuster; Chris-Ellyn Johanson
Journal:  Psychopharmacology (Berl)       Date:  2002-01-31       Impact factor: 4.530

7.  Buprenorphine sublingual tablets: effects on IV heroin self-administration by humans.

Authors:  S D Comer; E D Collins; M W Fischman
Journal:  Psychopharmacology (Berl)       Date:  2001-02       Impact factor: 4.530

8.  Cocaine and amphetamine attenuate the discriminative stimulus effects of naltrexone in opioid-dependent rhesus monkeys.

Authors:  Stacy L Sell; Charles P France
Journal:  J Pharmacol Exp Ther       Date:  2002-06       Impact factor: 4.030

9.  Long-term opiate effects on amphetamine-induced dopamine release in the nucleus accumbens core and conditioned place preference.

Authors:  Shaunteng He; Ning Li; Kenneth Grasing
Journal:  Pharmacol Biochem Behav       Date:  2004-02       Impact factor: 3.533

10.  Evidence that opioids may have toll-like receptor 4 and MD-2 effects.

Authors:  Mark R Hutchinson; Yingning Zhang; Mitesh Shridhar; John H Evans; Madison M Buchanan; Tina X Zhao; Peter F Slivka; Benjamen D Coats; Niloofar Rezvani; Julie Wieseler; Travis S Hughes; Kyle E Landgraf; Stefanie Chan; Stephanie Fong; Simon Phipps; Joseph J Falke; Leslie A Leinwand; Steven F Maier; Hang Yin; Kenner C Rice; Linda R Watkins
Journal:  Brain Behav Immun       Date:  2009-08-11       Impact factor: 7.217

View more
  17 in total

1.  Effects of 7-day continuous D-amphetamine, methylphenidate, and cocaine treatment on choice between methamphetamine and food in male rhesus monkeys.

Authors:  Kathryn L Schwienteck; Matthew L Banks
Journal:  Drug Alcohol Depend       Date:  2015-09-02       Impact factor: 4.492

2.  Caenorhabditis elegans as a model system to identify therapeutics for alcohol use disorders.

Authors:  Simon N Katner; Kristin E Bredhold; Kevin B Steagall; Richard L Bell; Bethany S Neal-Beliveau; Mi C Cheong; Eric A Engleman
Journal:  Behav Brain Res       Date:  2019-02-22       Impact factor: 3.332

3.  No evidence for reduction of opioid-withdrawal symptoms by cannabis smoking during a methadone dose taper.

Authors:  David H Epstein; Kenzie L Preston
Journal:  Am J Addict       Date:  2015-04-06

Review 4.  Agonist Medications for the Treatment of Cocaine Use Disorder.

Authors:  S Stevens Negus; Jack Henningfield
Journal:  Neuropsychopharmacology       Date:  2014-12-11       Impact factor: 7.853

Review 5.  Pharmacotherapies for decreasing maladaptive choice in drug addiction: Targeting the behavior and the drug.

Authors:  Frank N Perkins; Kevin B Freeman
Journal:  Pharmacol Biochem Behav       Date:  2017-06-27       Impact factor: 3.533

6.  Pharmacotherapeutic strategies for treating cocaine use disorder-what do we have to offer?

Authors:  Laura Brandt; Thomas Chao; Sandra D Comer; Frances R Levin
Journal:  Addiction       Date:  2020-09-28       Impact factor: 6.526

Review 7.  Utility of Nonhuman Primates in Substance Use Disorders Research.

Authors:  Matthew L Banks; Paul W Czoty; Sidney S Negus
Journal:  ILAR J       Date:  2017-12-01

8.  Effects of 5-HT2A receptor stimulation on economic demand for fentanyl after intermittent and continuous access self-administration in male rats.

Authors:  David Alexander Martin; Utsav Gyawali; Donna J Calu
Journal:  Addict Biol       Date:  2020-05-26       Impact factor: 4.280

9.  Effects of the novel, selective and low-efficacy mu opioid receptor ligand NAQ on intracranial self-stimulation in rats.

Authors:  Ahmad A Altarifi; Yunyun Yuan; Yan Zhang; Dana E Selley; S Stevens Negus
Journal:  Psychopharmacology (Berl)       Date:  2014-09-03       Impact factor: 4.530

10.  Evaluation of the Reinforcing Strength of Phendimetrazine Using a Progressive-Ratio Schedule of Reinforcement in Rhesus Monkeys.

Authors:  Molly Minkiewicz; Paul W Czoty; Bruce E Blough; Michael A Nader
Journal:  J Pharmacol Exp Ther       Date:  2020-04-08       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.